kinase D interacting substrate 220Genealiases: ARMS · SINO · VENARG
Q-omics provides the consensus-scored KIDINS220 profile across patient tissues and cancer cell-line models. KIDINS220 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIDINS220 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KIDINS220 RNA expression shows 22,667 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where KIDINS220 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIDINS220 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIDINS220 survival associations across molecular data types. KIDINS220 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIDINS220 RNA expression–survival associations across cancer types. High KIDINS220 expression shows unfavorable associations in BLCA and ACC, but favorable associations in KIRC, LUAD, SCLC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIDINS220 RNA expression.
This table summarizes KIDINS220 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KIDINS220. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIDINS220 shows lower tumor expression in KICH, BRCA and LUAD and higher tumor expression in HNSC, CHOL and LIHC. The HNSC box plot shows higher KIDINS220 RNA expression in tumor versus normal tissue (log2 FC = +0.875, t-test p < 0.001).
This table shows molecular features associated with KIDINS220 in patient tissues and cancer cell lines. In patient samples, KIDINS220 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIDINS220 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
